Swedish pharmaceutical company Dicot Pharma AB (Nasdaq First North:DICOT) announced on Thursday that it has received regulatory approval to initiate its phase 2b clinical study of LIB-01 in the European Union, with Sweden becoming the first participating EU country to grant authorisation. The clinical trial application also covers France and the Netherlands.
The study, which recently commenced in the United States, will evaluate LIB-01 as a potential treatment for erectile dysfunction through repeated monthly dosing at different dose levels. Following completion of the initial US study phase, Dicot Pharma expects to begin dosing participants in the EU during the efficacy evaluation phase.
The ongoing first part of the study aims to establish the highest dose for the efficacy assessment and is expected to conclude in the first quarter of 2027.
The adaptive phase 2b study will involve at least 200 participants across all severities of erectile dysfunction, evaluating planned doses of 25 mg, 50 mg and a higher dose to be determined. Results are expected to support dose selection for phase 3 development.
Ten63 Therapeutics launches BEYOND-Alpha early adopter programme
Eloxx Pharmaceuticals publishes Phase 2a exaluren data in nonsense mutation Alport syndrome
Bristol Myers Squibb reports first Phase 3 data for KarXT in Alzheimer's-related psychosis
Pfizer signs licensing agreement with Starna Therapeutics worth up to USD2.63bn
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
Dicot Pharma initiates phase 2b clinical study of erectile dysfunction drug candidate
Sobi's Tryngolza for severe hypertriglyceridaemia receives EU approval
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial
Rakuten Medical launches Phase 1 first-in-human trial of PD-L1-targeted RM-0256 photoimmunotherapy
BioArctic and Eisai report positive five-year data for Leqembi in early Alzheimer's disease
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer
AstraZeneca rare disease unit secures US and EU approvals for Klygefa in myasthenia gravis
Genentech secures first FDA approval for primary membranous nephropathy treatment